A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer
Related Posts
Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch[...]
Galamgam J, Baroni E, Tsai S, Cheng CE. Improvement of pruritus associated with erythrocytosis in transmasculine patients undergoing gender-affirming therapy with phlebotomy: a report of[...]
Le X, Robichaux JP, Nilsson M, Vijayan RSK, Ravichandran A, Wu J, Elamin YY, Hong L, Pei J, He J, Patel S, Udagawa H, Mani[...]